US Patent

US8765150 — Riluzole aqueous suspensions

Method of Use · Assigned to Italfarmaco SpA · Expires 2029-03-12 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of making and a formulation for physically and chemically stable aqueous oral suspensions of the drug riluzole.

USPTO Abstract

Physically and chemically stable aqueous oral suspensions of riluzole and manufacturing methods thereof. The suspensions contain riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is present in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 μm. The suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2401 — Rilutek

Patent Metadata

Patent number
US8765150
Jurisdiction
US
Classification
Method of Use
Expires
2029-03-12
Drug substance claim
No
Drug product claim
Yes
Assignee
Italfarmaco SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.